Eli Lilly and Company (NYSE:LLY) Trading 2.5% Higher – Should You Buy?

Posted by Geri Gentry on Jul 23rd, 2026

Eli Lilly and Company logo Eli Lilly and Company (NYSE:LLY – Get Free Report) traded up 2.5% during trading on Tuesday . The company traded as high as $1,177.58 and last traded at $1,175.15. 2,076,317 shares changed hands during mid-day trading, a decline of 34% from the average daily volume of 3,165,183 shares. The stock had previously closed at $1,146.90.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Eli Lilly reported positive Phase 3 results for retatrutide in two additional obesity trials, with the drug producing substantial weight loss and improvements in blood sugar measures. The company said it now plans to submit the FDA application in the first quarter of 2027, strengthening confidence in Lilly’s obesity pipeline and future revenue potential. Reuters article: Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application
Positive Sentiment: The same retatrutide data showed very strong weight-loss results in difficult-to-treat patient groups, including adults with obesity and type 2 diabetes and those with severe obesity and cardiovascular disease, reinforcing Lilly’s leadership in the GLP-1 and next-generation obesity market. PR Newswire article: Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials
Neutral Sentiment: Several reports noted that Lilly is preparing regulatory materials and that analysts remain focused on the company’s earnings and broader GLP-1 portfolio, which keeps investor expectations high ahead of the next earnings update. WSJ article: Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Negative Sentiment: Weight-loss rival Novo Nordisk filed a lawsuit accusing Eli Lilly of misleading advertising around Zepbound and Mounjaro, claiming Lilly used outdated clinical comparisons. While this is unlikely to change fundamentals immediately, it could create headline risk and some short-term overhang. Reuters article: Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on LLY shares. Rothschild & Co Redburn boosted their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Barclays lifted their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. Bank of America lifted their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday, July 10th. Finally, Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,283.64.

Check Out Our Latest Report on LLY

Eli Lilly and Company Trading Down 1.0%

The stock has a market cap of $1.10 trillion, a price-to-earnings ratio of 41.34, a P/E/G ratio of 1.49 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The business’s 50 day moving average is $1,129.17 and its 200 day moving average is $1,038.31.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 34.21 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Institutional Trading of Eli Lilly and Company

Several hedge funds have recently made changes to their positions in LLY. Vanguard Group Inc. grew its holdings in Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after acquiring an additional 1,006,885 shares during the period. State Street Corp increased its stake in Eli Lilly and Company by 1.8% in the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after purchasing an additional 635,358 shares in the last quarter. Morgan Stanley grew its holdings in Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after purchasing an additional 407,166 shares during the last quarter. Capital World Investors boosted its position in shares of Eli Lilly and Company by 0.4% in the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after buying an additional 61,851 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Eli Lilly and Company by 10.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after acquiring an additional 1,432,069 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.